BridgeBio Pharma (BBIO) is in focus after releasing highly positive topline data from its pivotal Phase 3 PROPEL 3 trial of oral infigratinib in children with achondroplasia, meeting key efficacy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results